4basebio AG: 4basebio AG decides to increase the public share buyback offer volume from 2,056,452 to 5,230,726 shares

Ad hoc Release according to Art. 17 Market Abuse Regulation

4basebio AG decides to increase the public share buyback offer volume from 2,056,452 to 5,230,726 shares

Heidelberg, Germany, and Cambridge, UK, 10 February 2020 - The management board of 4basebio AG (formerly Expedeon AG) (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) has decided today, to increase the original volume of the current public share buyback offer from 2,056,452 to 5,230,726 shares and thus to acquire now shares up to 5,230,726.

The acceptance period ends on 10 February 2020, 12:00 noon (local time Frankfurt am Main). If more than 5,230,726 shares are submitted for buyback under the offer, the declarations of acceptance will be considered in proportion to the ratio of the 5,230,726 shares to the total number of shares submitted for buyback by the shareholders.

Further details of the public buyback offer can be found in the offer document, which was published on 24 January 2020 on the Company’s website (www.investors.4basebio.com) under the heading “News” and in the German Federal Gazette (Bundesanzeiger).

*** end of ad hoc announcement ***

For further information, please contact:

4basebio AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: [email protected]
Investors’ information: investors.4basebio.com

MC Services AG (Investor Relations and International Media Relations)

Julia Hofmann
Phone: +49 89 210228 0
Email: [email protected]

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of 4basebio AG may deviate greatly from the established conclusions or implied predictions contained in such statements. 4basebio does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###

Contact:
David Roth
Vorstand/ CFO

Expedeon AG

Waldhofer Str. 102
69123 Heidelberg, GERMANY

Tel. +49 6221 3540 125
Fax. +49 6221 3540 127